A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions

Trial Profile

A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs MRX 34 (Primary) ; Dexamethasone; Dexamethasone
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacokinetics
  • Acronyms MRX34-102
  • Sponsors Mirna Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top